EGFR-Mutant Lung Cancer in 2018
May 08, 2018 | Online

Overview

This webinar will review the current data and best practices for treatment of stage IV EGFR mutation-positive lung cancer. It will address how to integrate the changing standards of care for wild-type patients with target-driven cancer algorithms. The following topics will be covered:

  • What are the ideal treatment regimens for 1st line and 2nd line
  • How do we integrate immune therapy into the care of patients with driver oncogenes
  • What are the areas of unmet need

What you should expect to learn

At the end of this webinar participants will be able to:

  • Review the current data relative to the treatment of stage IV EGFR mutation-positive lung cancer.
  • Identify and discuss best practices for the treatment of EGFR-mutant lung cancer.
  • Address how to integrate the changing standards of care for wild-type patients with target driven cancer algorithms.
  • Identify areas of unmet needs.

Lecia V. Sequist, MD, MPH
The Landry Family Associate Professor of Medicine, Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital 

 Ramaswamy Govindan, MD - Program Chair

Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Contact